Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Abstract

Venetoclax (VEN) in combination with low-dose cytarabine (LDAC) is FDA-approved for the treatment of unfit patients with newly diagnosed AML ineligible for intensive chemotherapy, based on a response rate of 54% (complete remission with or without blood count recovery [CR/CRi]) in the original phase Ib/II study.1 The VIALE-C phase 3 study (ClinicalTrials.gov Identifier: NCT03069352), compared VEN vs placebo (PBO) in combination with LDAC in 211 patients with untreated AML ineligible for intensive chemotherapy.

Keywords

• VIALE-C
• patients
• untreated AML
• intensive chemotherapy